09:29 AM EST - BioVaxys Technology Corp : Announced it has received a Notice of Allowance from the United States Patent and Trademark Office for a Patent for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX™. Part of the extensive Intellectual Property portfolio acquired by BioVaxys from the former IMV, Inc, this Patent was recently allowed in Japan and is currently pending in the European Union. DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells to be attracted to the injection site, facilitating a robust and sustained immune response. BioVaxys Technology Corp
shares C.BIOV are trading up one cent at $0.08.
